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Background: Irritable bowel syndrome is a chronic condition with no known cure. Many sufferers seek
complementary and alternative medicine including homeopathic treatment. However there is much controversy as
to the effectiveness of homeopathic treatment. This three-armed study seeks to explore the effectiveness of
individualised homeopathic treatment plus usual care compared to both an attention control plus usual care and
usual care alone, for patients with irritable bowel syndrome.
Methods/design: This is a three-armed pragmatic randomised controlled trial using the cohort multiple
randomised trial methodology. Patients are recruited to an irritable bowel syndrome cohort from primary and
secondary care using GP databases and consultants lists respectively. From this cohort patients are randomly
selected to be offered, 5 sessions of homeopathic treatment plus usual care, 5 sessions of supportive listening plus
usual care or usual care alone. The primary clinical outcome is the Irritable Bowel Syndrome Symptom Severity at
26 weeks.
From a power calculation, it is estimated that 33 people will be needed for the homeopathic treatment arm and
132 for the usual care arm, to detect a minimal clinical difference at 80 percent power and 5 percent significance
allowing for loss to follow up. An unequal group size has been used for reasons of cost. Analysis will be by
intention to treat and will compare homeopathic treatment with usual care at 26 weeks as the primary analysis,
and homeopathic treatment with supportive listening as an additional analysis.
Discussion: This trial has received NHS approval and results are expected in 2013.
Trial registration: Current Controlled Trials ISRCTN90651143
Keywords: Irritable bowel syndrome, Homeopathic treatment, Attention control, Randomised controlled trialBackground
Irritable Bowel Syndrome (IBS) is a common, chronic
disorder that affects approximately 10% - 22% of the
population [1]. It is characterised by abdominal pain or
discomfort and altered bowel habits, and may also be ac-
companied by bloating, nausea and vomiting and early
satiety. IBS is a functional gastrointestinal disorder.
Functional gastrointestinal disorders are difficult to treat
because no single aetiology is known and thus treatment
is directed at controlling symptoms, using pharmaco-
logical and non-pharmacological approaches. There are
an estimated 240,000 primary care consultations per
year in the UK of new cases of IBS [2] and the economic* Correspondence: hcejp@leeds.ac.uk
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reproduction in any medium, provided the orcosts of IBS in primary care are estimated to be over
£200 million [3]. IBS is diagnosed using the Rome cri-
teria, the most recent being Rome III [4], or on the basis
of clinical symptoms with the absence of alarm signs
(signs that indicate the potential presence of a serious
disease). There are four subtypes: IBS-C constipation
predominant, IBS-D diarrhoea predominant, IBS-M
mixed and IBS-unspecified.
The prognosis for recovery with IBS is poor. A one
year prospective evaluation found that although 50% of
patients improved over the year, improvement was
minor in terms of IBS symptoms such as pain, constipa-
tion and diarrhoea [5]. This could lead to the patients’
quality of life being adversely affected resulting in
depressed mood, sleep disturbance and fatigue [6,7]. IBS
is associated with high healthcare utilisation costs and
loss of productivity [8,9]. Despite much research intoal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Standard RCT for homeopathic treatment.
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there is no consensus as to its optimal treatment [10].
A significant proportion of patients with gastrointes-
tinal disorders use complementary or alternative medi-
cine, between 11% and 43% according to one systematic
review [11]. Gastroenterology problems are the fourth
most common referral to NHS homeopathic hospitals
[12] and one of the eight most common conditions trea-
ted by NHS homeopaths in general practice [13], with ir-
ritable bowel syndrome being the tenth most common
condition seen by NHS homeopathic hospitals [14].
There is currently a degree of scepticism regarding
homeopathic treatment with claims that it is a placebo
treatment and therefore unethical [15]. Much of the
criticism focuses on the opinion that the homeopathic
medicine is no more than a placebo [16] and it is the
long consultation time with an empathetic practitioner
that leads to any perceived effectiveness of homeopathic
treatment [17].
A literature search for trials of homeopathic treatment
for IBS using the search terms ‘irritable bowel syndrome’,
or ‘irritable colon’ and ‘homeopathy’ identified many case
reports e.g. a clinical audit [18], one consecutive case
series [19] and three randomised controlled trials [20-22].
Two randomised controlled trials (RCTs) assessing the
effectiveness of one specific homeopathic medicine (asa-
foetida) reported positive results associated with homeo-
pathic medicine compared to placebo [20,21] and one
found no difference between homeopathic treatment
and usual care [22]. In the consecutive case series [19],
twenty out of twenty five patients reported an improve-
ment in the intensity and frequency of their symptoms. In
spite of its popularity in the treatment of gastroenterology
disorders there is a lack of robust evidence as to the effect-
iveness of homeopathic treatment for IBS and thus there
is a need for further research into the clinical effectiveness
of homeopathic treatment for patients with IBS.
The majority of previous trials of homeopathic treat-
ment focus on the homeopathic medicine as the key in-
gredient and as such compare changes in health of
subjects having a homeopathic consultation plus a
homeopathic medicine with changes in health in sub-
jects having a homeopathic consultation plus a placebo
medicine, Figure 1 shows a schematic of the standard
RCT for homeopathic treatment. Studies using the de-
sign depicted in Figure 1 are only able to assess the ef-
fect of the homeopathic medicine and are not able to
assess the effect of homeopathic treatment as a package,
(the homeopathic consultation plus the homeopathic
medicine). There has been much debate as to whether
or not this is an appropriate design to determine the ef-
ficacy of homeopathic treatment [23], in part because
the traditional homeopathic medicine versus placebo
medicine design fails to take into account any aspectsspecific to the homeopathic consultation. Furthermore
the homeopathic approach is best understood as a com-
plex intervention with component parts (consultation
and medicine) consequently the design of an appropriate
control is less straightforward than would be the case if
a drug therapy alone were being evaluated. Pragmatic
trials comparing homeopathic treatment (as a package of
consultation plus homeopathic medicine) to usual care
provide a means of assessing the effect of homeopathic
treatment as a package. However the lack of a compari-
son intervention in the homeopathic treatment plus
usual care versus usual care design leads to the question
as to whether any observed effectiveness of homeopathic
treatment is due to non-specific effects of spending time
with an empathetic practitioner. A possible solution to
this problem is to compare homeopathic treatment to
an “attention control” designed to control for the time
and attention that the patient spends with/receives from
the homeopath. Whilst other studies have been con-
ducted to assess the effect of the homeopathic consult-
ation, [17,24] as yet no studies have attempted to
compare the whole package of homeopathic treatment
to a control intervention as a means of assessing the
effects of homeopathic treatment.
For this study supportive listening was chosen as the
“attention control”. Supportive listening is a non-specific
treatment that has been used in previous trials of psy-
chological therapies for IBS [25]. It has in the past been
used to control for the non-specific aspects of therapy
including the time that the patient spends with the prac-
titioner, empathy and positive regard [26]. Supportive
listening is not formal counselling per se [27], and al-
though based on the theories of Carl Rogers and utilis-
ing the skills of active listening, it does not include the
more advanced Rogerian skills such as challenging,
problem clarification and accurate understanding [27].
Including supportive listening as one of the arms in a
RCT of homeopathic treatment allows homeopathic
treatment to be compared to spending time with a car-
ing and empathetic practitioner. Supportive listening
was chosen as an “attention control” because it contains
the non-specific factors of homeopathic treatment such
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containing the specific effects such as the homeopathic
medicine and the in-depth enquiry into bodily com-
plaints. A supportive listening arm will be included in
this trial to test the feasibility of supportive listening as
an attention control for homeopathic treatment, in the
treatment of IBS. In addition, a usual care arm is
included in the trial, this is to put the results into con-
text and allow an assessment to be made as to whether
homeopathic treatment in addition to usual care offers
any benefits over usual care alone.
Therefore, in this study we are attempting to assess
whether homeopathic treatment (consultation plus
homeopathic medicine) is more effective than usual care
alone and whether homeopathic treatment is any more
effective than spending time with an empathetic and car-
ing practitioner as assessed by change in IBS symptom
severity score (IBS-SSS) between baseline and 26 weeks.
This study aims to test the whole intervention of
“homeopathic treatment”. It is not aiming to, and nor is
it designed to, give new insights into the question as to
the effects of homeopathic medicines per se. Results of
this study will report the clinical effectiveness of homeo-
pathic treatment plus usual care compared to usual care
alone, and provide information on the feasibility of in-
cluding a supportive listening arm as an attention con-
trol for homeopathic treatment, for patients with IBS.
Additionally the supportive listening arm will provide in-
formation on effect size and variation, information
which will enable future investigators to more accurately
estimate the sample size required for a full scale trial
comparing homeopathic treatment to supportive
listening.
The aims of this study are:
▪ to evaluate the clinical effectiveness of homeopathic
treatment plus usual care as compared to usual care
alone for patients with IBS.
▪ to test whether supportive listening is a feasible
attention control for homeopathic treatment.
Methods
This study uses the Cohort multiple RCT design [28].
This design was chosen because it allows a number of
RCTs to be carried out using a single cohort of people
with IBS, see below. This permits increased comparabil-
ity between trials conducted within the cohort and
allows for data to be collected on the natural history of
the condition.
Identification and recruitment
The Cohort multiple RCT design involves the recruit-
ment of a cohort of people to an observational study.
These people agree to be observed over time forresearch purposes through completing questionnaires.
Those in the cohort may then subsequently be identified
as eligible to take part in one or more RCTs. The cohort
used in this study (termed the Barnsley irritable bowel
syndrome cohort (BIBSC)) was set up specifically for this
study. However there is the potential for other RCTs to
be carried out in the future using the BIBSC. Once iden-
tified as eligible to take part in this RCT participants are
either randomly selected to be offered a treatment (in
this instance supportive listening or homeopathic treat-
ment) or randomly selected to make up the control arm
of the RCT. Patients who are randomly selected to one
of the two treatment arms give their consent to treat-
ment at this point. Figure 2 shows a flow diagram of this
process.
Potentially eligible participants for recruitment to the
IBS cohort are identified through two routes:
Primary care: GP databases are searched for the names
and addresses of patients aged over 18 with a diagnosis
of IBS or given medications used to treat IBS symptoms
and who have consulted their GP for IBS within the last
two years.
Secondary care: Patients are identified by Gastro-
enterological clinicians at Barnsley Hospital.
The Episode study [29] has shown that the burden of
symptoms of patients with IBS in primary care is similar
to the burden of symptoms of those in secondary care;
therefore no attempt will be made to stratify by recruit-
ment route.
Those identified as potentially eligible for recruitment
to the IBS cohort are sent a letter inviting them to take
part in an observational study along with a questionnaire
to complete and return. This questionnaire forms the
baseline questionnaire and is used to identify those eli-
gible for the RCT and the cohort.
There are two sets of inclusion criteria for this study,
inclusion criteria for the cohort and inclusion criteria for
the RCT study. Figure 3 gives the inclusion and exclu-
sion criteria for both the RCT and the Cohort.
Randomisation and blinding
Eligible participants are randomised to, homeopathic
treatment plus usual care or supportive listening plus
usual care or usual care alone by the shuffling of sealed
opaque envelopes containing the allocation. Question-
naires from participants consenting and meeting the eli-
gibility criteria are taken one at a time, at the same time
a sealed opaque envelope containing the allocation is
taken from the top of the shuffled pack and opened and
the allocation noted. This is carried out by an independ-
ent administrator at the University of Sheffield, in the
presence of another independent administrator. Letters
offering treatment are then sent to those randomly allo-
cated to one of the two active treatment arms.
Sent questionnaire (n= )
Returned questionnaire and assessed 
for eligibility to Cohort (n= )
Excluded (n= )
Not meeting inclusion criteria (n= )
Failed to consent (n= )
Other reasons (n= )
Allocated to Supportive listening 
plus usual care (n= )
Received allocated intervention 
(n= )
Did not receive allocated 
intervention (n= ) (give reasons)
Randomised (n= )
Excluded (n= )
Not meeting inclusion criteria (n= )
Other reasons ( n= )
Assessed for eligibility to RCT (n= ) 
Allocated to Usual care 
(n= )
Allocated to homeopathic 
treatment plus usual care (n= )
Received allocated intervention 
(n=) 
Did not receive allocated 
intervention (n= ) (give reasons)
26 week outcomes
52 week outcomes
Lost to follow up (n= ) 
(give reasons)
Lost to follow up (n= )
(give reasons)
Discontinued intervention (n= ) 
(give reasons)
Lost to follow up (n= )
(give reasons)
Discontinued intervention (n= ) 
(give reasons)
Analysed (n= ) 
Excluded from analysis (n= )
(give reasons)
Analysed (n= ) 
Excluded from analysis (n= 
)(give reasons)
Analysed (n= ) 
Excluded from analysis (n= 
)(give reasons)
Analysed (n= ) 
Excluded from analysis (n= )
(give reasons)
Analysed (n= ) 
Excluded from analysis (n= )
(give reasons)
Analysed (n= ) 
Excluded from analysis (n= )
(give reasons)
Lost to follow up (n= ) 
(give reasons)
Lost to follow up (n= )
(give reasons)
Discontinued intervention (n= ) 
(give reasons)
Lost to follow up (n= )
(give reasons)
Discontinued intervention (n= ) 
(give reasons)
Figure 2 Flow diagram for trial showing intervention and non-intervention arms.
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nor the study design allows for the masking of the thera-
pists or the participants. However data are inputted and
analysed blind to treatment allocation.
Interventions
Participants allocated to the offer of homeopathic treat-
ment or the offer of supportive listening are offered upto five one hour appointments at Barnsley Hospital over
a six month period. Due to the pragmatic nature of this
trial it will be for the participants to decide as to
whether or not they attend all five sessions, however
they will be encouraged to attend appointments as
would be the case in usual practice. All participants re-
main in the care of their GP and continue to receive
their usual NHS treatments. Homeopathic treatment
Cohort 
Inclusion criteria
Aged 18 or over
IBS as defined by the ROME III criteria
Consent to fill in and return postal questionnaires
RCT
Inclusion criteria Exclusion criteria
Score of more than 100 on IBS SSS Current diagnosis of haemophilia, cancer or
Fluent in English Unstable mental or psychiatric illness
Major gastrointestinal surgery in the last 6 months
Currently receiving homeopathic treatment
Pregnant or breastfeeding women
Figure 3 Inclusion and exclusion criteria.
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prescription of a homeopathic medicine and is provided
by professional homeopaths registered with the Society
of Homeopaths with at least five years experience. The
homeopaths providing treatment in this study do not
have a particular specialism in IBS, however they have
taken part in a previous trial assessing the effectiveness
of homeopathic treatment for fibromyalgia [30]. The
homeopaths can choose from any of the homeopathic
medicines in the homeopathic pharmacopeia.
Supportive listening is based on the theories and coun-
selling techniques of Carl Rogers [31] and involves active
listening skills such as empathising, reflecting, summar-
ising and paraphrasing. In the sessions patients are able
to talk about their physical symptoms as well as any
emotional issues and possible ways of coping with these
better. It provides patients with the opportunity to ex-
press themselves and feel heard in a non-judgemental
environment. The sessions are delivered by trained psy-
chotherapists registered with either the British Associ-
ation for Counselling & Psychotherapy or the United
Kingdom Register of Counsellors and Psychotherapists.
For intervention fidelity, and to ensure that the practi-
tioners delivering the supportive listening are delivering
supportive listening rather than Cognitive Behavioural
Therapy or any other counselling intervention, a random
selection of sessions is taped and assessed by an inde-
pendent assessor, who will describe the approaches used.
The patients’ perceptions of the effects of interven-
tions and their acceptability to patients will be assessed
in a nested qualitative study exploring patient and prac-
titioner experiences of delivering and receiving treat-
ment within the trial. This qualitative study will take the
form of hour-long semi-structured interviews aimed at
eliciting information about what, it anything patients
perceive to have led to any improvement in their IBS or
general health. The aim being to explore patients per-
ceptions of the treatment they received, what, if anything
they believe led to any effectiveness the treatment and
their views on the acceptability of the treatment. It is the
intention to publish full details of the qualitative study at
a later date.Outcome measures
The primary outcome measure is the IBS Symptom Se-
verity Scoring (IBS-SSS) [32]. Secondary outcome mea-
sures are the Hospital Anxiety and Depression scale
(HADs) [33] and EQ-5D [34]. The EQ-5D was chosen as
the quality of life measure rather than a disease specific
measure such as the IBS quality of life measure (IBS-
QOL) [35] because the EQ-5D was required for the cost
effectiveness component of this study. Therefore to re-
duce the burden of filling out multiple questionnaires on
patients it was decided to utilise solely the EQ-5D rather
than an additional disease specific health related quality
of life measure.
Cost effectiveness is calculated using the EQ-5D, a
measure of health related quality of life along with data
collected on medication and health services usage and
absences from work.
The credibility of the treatments to the patients is
assessed using a validated measure originally designed
by Borkovec [36] and modified by Drossman [37] for
IBS. A single measurement at 26 weeks is made using
the CARE empathy measure for participants in either
the homeopathic treatment or supportive listening arms
[38]. This is a measure of the practitioner’s empathy as
perceived by the patients.
Outcomes are sought by postal questionnaire at base-
line, 26 weeks and 52 weeks. The primary endpoint of
this study is 26 weeks, whilst the 52 week questionnaire
will provide data on the longer term effectiveness of the
interventions.
Sample size
The RCT sample size calculation has been based on the
primary outcome, which is the change in IBS-SSS be-
tween baseline and 26 weeks. The IBS-SSS is based on a
series of visual analogue scales (VAS) and has been vali-
dated for use in assessing IBS severity. It is scored be-
tween 0 and 500 and a higher score indicates more
severe IBS. A change of 50 points is considered to be a
clinically relevant change [32]. It has been suggested that
VAS scales are of greater value when used to determine
change within individuals rather than being used to
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individuals [39]. Therefore change in IBS-SSS is used ra-
ther than an endpoint score. This study has been pow-
ered to detect a difference between homeopathic
treatment and usual care. Powering to detect a difference
between homeopathic treatment and supportive listening
was considered but found to be beyond the resources of
this study. However the study will still be able to provide
information on the feasibility of supportive listening as
an attention control for homeopathic treatment.
A 4:1:1 ratio of usual care: homeopathic treatment:
supportive listening was chosen for this trial because of
cost limitations. The cost of providing homeopathic
treatment or supportive listening was higher than costs
associated with the usual care arm of the trial. Using un-
equal group size provides a means of reducing the cost
of a trial whilst maintaining power [40]. A power calcu-
lation was carried out using sample size determination
software called PS Power [41]. Assuming use of an inde-
pendent t test to compare groups, power 80%, signifi-
cance level 5%, clinically relevant change of 50 on the
IBS-SSS [32] and based on previous RCTs [42-44] stand-
ard deviation of 85, ratio of usual care to homeopathic
treatment of 4:1, 29 participants are required for the
homeopathic treatment and supportive listening arms
and 116 for the usual care arm for this comparison. In a
previous IBS study [45] it was found that there was a
13% loss to follow up and taking this into account
increases the estimated sample size to 33 for the homeo-
pathic treatment and supportive listening arms and 132
for the usual care arm. Therefore in total 198 people will
be required for this study, 33 people for each of the
homeopathic treatment and supportive listening arms
and 132 people for the usual care arm.
Data analysis
Descriptive statistics and a CONSORT type flow diagram
[46] are used to describe the flow of all participants
through the trial. The following baseline patient charac-
teristics are reported for all participants meeting the
RCT criteria: age, IBS-SSS, HAD score, number of pre-
scribed/self prescribed medications, medication total and
EQ-5D score. Baseline data on those who accepted the
offer of treatment and those who refused are compared
to assess whether there are any differences between those
who accepted and those who declined treatment.
Data are analysed on an intention to treat basis using
a 2-sided 5% significance level. All participants are
included in the group they were randomised to regard-
less of whether they received their allocated treatment.
The primary outcome is the mean change in IBS-SSS be-
tween baseline and 26 weeks assessed using analysis of
covariance adjusting for baseline scores. The percentage
of those achieving a clinically relevant change of 50points on the IBS-SSS will be reported for each of the
three groups. The mean change in HADS between base-
line and 26 weeks will also be assessed using analysis of
covariance adjusting for baseline scores. All data are
tested for normality and where normality is not met the
equivalent nonparametric tests will be used.
Discussion
This research received ethics approval from the Leeds
East Research Ethics Committee (10H/1306/73).
Results are expected in 2013.
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